The neurotrophic protein S100B

value as a marker of brain damage and possible therapeutic implications

Andrea Kleindienst, Felicitas Hesse, Ross Bullock, Michael Buchfelder

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

We provide a critical analysis of the value of S100B as a marker of brain damage and possible therapeutic implications. The early assessment of the injury severity and the consequent prognosis are of major concern for physicians treating patients suffering from traumatic brain injury (TBI). A reliable indicator to accurately determine the extent of the brain damage has to meet certain requirements: (i) to originate in the central nervous system (CNS) with no contribution from extracerebral sources; (ii) a passive release from damaged neurons and/or glial cells without any stimulated active release; (iii) a lack of specific effects on neurons and/or glial cells interfering with the initial injury; (iv) an unlimited passage through the blood-brain barrier (BBB). The measurement of putative biochemical markers, such as the S100B protein, has been proposed in this role. Over the past decade, numerous studies have reported a positive correlation of S100B serum levels with a poor outcome following TBI. However, some studies raise doubt whether the serum measurement of S100B is a valid biochemical marker of brain damage. We summarize the specific properties of S100B and analyze whether they support or counteract the necessary requirements to designate this protein as an indicator of brain damage. Finally, we report recent experimental findings suggesting a possible therapeutic potential of S100B.

Original languageEnglish
Pages (from-to)317-325
Number of pages9
JournalProgress in Brain Research
Volume161
DOIs
StatePublished - Jul 6 2007
Externally publishedYes

Fingerprint

Nerve Growth Factors
Brain
Neuroglia
Biomarkers
Neurons
Wounds and Injuries
Therapeutics
Blood-Brain Barrier
Serum
Proteins
Central Nervous System
Physicians
Traumatic Brain Injury

Keywords

  • biomarker
  • brain damage
  • neuroregeneration
  • neurotrophic factor
  • S100B
  • TBI

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The neurotrophic protein S100B : value as a marker of brain damage and possible therapeutic implications. / Kleindienst, Andrea; Hesse, Felicitas; Bullock, Ross; Buchfelder, Michael.

In: Progress in Brain Research, Vol. 161, 06.07.2007, p. 317-325.

Research output: Contribution to journalArticle

Kleindienst, Andrea ; Hesse, Felicitas ; Bullock, Ross ; Buchfelder, Michael. / The neurotrophic protein S100B : value as a marker of brain damage and possible therapeutic implications. In: Progress in Brain Research. 2007 ; Vol. 161. pp. 317-325.
@article{6fc40b4d265047aabfd9d165133db6fc,
title = "The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications",
abstract = "We provide a critical analysis of the value of S100B as a marker of brain damage and possible therapeutic implications. The early assessment of the injury severity and the consequent prognosis are of major concern for physicians treating patients suffering from traumatic brain injury (TBI). A reliable indicator to accurately determine the extent of the brain damage has to meet certain requirements: (i) to originate in the central nervous system (CNS) with no contribution from extracerebral sources; (ii) a passive release from damaged neurons and/or glial cells without any stimulated active release; (iii) a lack of specific effects on neurons and/or glial cells interfering with the initial injury; (iv) an unlimited passage through the blood-brain barrier (BBB). The measurement of putative biochemical markers, such as the S100B protein, has been proposed in this role. Over the past decade, numerous studies have reported a positive correlation of S100B serum levels with a poor outcome following TBI. However, some studies raise doubt whether the serum measurement of S100B is a valid biochemical marker of brain damage. We summarize the specific properties of S100B and analyze whether they support or counteract the necessary requirements to designate this protein as an indicator of brain damage. Finally, we report recent experimental findings suggesting a possible therapeutic potential of S100B.",
keywords = "biomarker, brain damage, neuroregeneration, neurotrophic factor, S100B, TBI",
author = "Andrea Kleindienst and Felicitas Hesse and Ross Bullock and Michael Buchfelder",
year = "2007",
month = "7",
day = "6",
doi = "10.1016/S0079-6123(06)61022-4",
language = "English",
volume = "161",
pages = "317--325",
journal = "Progress in Brain Research",
issn = "0079-6123",
publisher = "Elsevier",

}

TY - JOUR

T1 - The neurotrophic protein S100B

T2 - value as a marker of brain damage and possible therapeutic implications

AU - Kleindienst, Andrea

AU - Hesse, Felicitas

AU - Bullock, Ross

AU - Buchfelder, Michael

PY - 2007/7/6

Y1 - 2007/7/6

N2 - We provide a critical analysis of the value of S100B as a marker of brain damage and possible therapeutic implications. The early assessment of the injury severity and the consequent prognosis are of major concern for physicians treating patients suffering from traumatic brain injury (TBI). A reliable indicator to accurately determine the extent of the brain damage has to meet certain requirements: (i) to originate in the central nervous system (CNS) with no contribution from extracerebral sources; (ii) a passive release from damaged neurons and/or glial cells without any stimulated active release; (iii) a lack of specific effects on neurons and/or glial cells interfering with the initial injury; (iv) an unlimited passage through the blood-brain barrier (BBB). The measurement of putative biochemical markers, such as the S100B protein, has been proposed in this role. Over the past decade, numerous studies have reported a positive correlation of S100B serum levels with a poor outcome following TBI. However, some studies raise doubt whether the serum measurement of S100B is a valid biochemical marker of brain damage. We summarize the specific properties of S100B and analyze whether they support or counteract the necessary requirements to designate this protein as an indicator of brain damage. Finally, we report recent experimental findings suggesting a possible therapeutic potential of S100B.

AB - We provide a critical analysis of the value of S100B as a marker of brain damage and possible therapeutic implications. The early assessment of the injury severity and the consequent prognosis are of major concern for physicians treating patients suffering from traumatic brain injury (TBI). A reliable indicator to accurately determine the extent of the brain damage has to meet certain requirements: (i) to originate in the central nervous system (CNS) with no contribution from extracerebral sources; (ii) a passive release from damaged neurons and/or glial cells without any stimulated active release; (iii) a lack of specific effects on neurons and/or glial cells interfering with the initial injury; (iv) an unlimited passage through the blood-brain barrier (BBB). The measurement of putative biochemical markers, such as the S100B protein, has been proposed in this role. Over the past decade, numerous studies have reported a positive correlation of S100B serum levels with a poor outcome following TBI. However, some studies raise doubt whether the serum measurement of S100B is a valid biochemical marker of brain damage. We summarize the specific properties of S100B and analyze whether they support or counteract the necessary requirements to designate this protein as an indicator of brain damage. Finally, we report recent experimental findings suggesting a possible therapeutic potential of S100B.

KW - biomarker

KW - brain damage

KW - neuroregeneration

KW - neurotrophic factor

KW - S100B

KW - TBI

UR - http://www.scopus.com/inward/record.url?scp=34347345970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347345970&partnerID=8YFLogxK

U2 - 10.1016/S0079-6123(06)61022-4

DO - 10.1016/S0079-6123(06)61022-4

M3 - Article

VL - 161

SP - 317

EP - 325

JO - Progress in Brain Research

JF - Progress in Brain Research

SN - 0079-6123

ER -